The PEER program provides an extraordinary opportunity to promote research cooperation between the Philippines and researchers funded by or based at nine US federal science agencies including: National Aeronautics and Space Administration (NASA), National Institute of Food and Agriculture (NIFA), National Institutes of Health (NIH), National Science Foundation (NSF), National Oceanic and Atmospheric Administration (NOAA), Smithsonion Institution, US Forest Service (USFS), Agriculture Research Service (ARS), and US Geological Survey (USGS).


The PEER program is designed to support research projects in USAID countries which address local and global development challenges.

The PEER Cycle 9 Funding Opportunities for Philippine researchers include:

  • Any development-related research
  • Family Planning and Reproductive Health
  • Social, Economic, and Behavioral Sciences

The application deadline to submit a brief pre-proposal to the PEER program is on February 10, 2020. For additional info, applicants are encouraged to consult

Reposted from
Written by Lyn Resurreccion

THE first anti-dengue medicine in the world may be available by end of next year. And, also significant, it is made by Filipino researchers in the Philippines.

Dr. Rita Grace Y. Alvero, program leader of the dengue herbal clinical trial from Pharmalytics Corp., told the “Talakayang HeaRTbeat” on Monday that the researchers from Pharmalytics and De La Salle Medical and Health Sciences Institute have concluded Phase 1 of the clinical trial for the drug against dengue that they got from three plant components. They are hopeful that it will be approved for marketing by the end of 2020.

“We have completed the preclinical testing. We have completed the safety analysis in animals. We are now in the human testing. We have just concluded the Phase 1 clinical trial. [Based on] our findings, there was no dose-limiting toxicity,” Alvero said, partly in Filipino.

She explained that the last cohort, or people who took the medicine, took 106 capsules of 400 mg of its three plant components and no toxicity was observed.

“We will probably start Phase 2 and Phase 3 by the first quarter of next year. We will end by the third quarter. [Then] we will apply for marketing authorization. Hopefully, by the end of 2020, the anti-dengue drug may be out [in the market],” Alvero explained in citing the details of the process of making the drug.

Her announcement was met with a round of applause from Department of Science and Technology (DOST) officials, including Secretary Fortunato T. de la Peña, Undersecretary Rowena Cristina Guevara and Director Dr. Jaime Montoya of the Philippine Council for Health Research and Development (PCHRD), and experts Dr. Gisela Concepcion of University of the Philippines-Diliman, Dr. Irene Villaseñor of UP Diliman and Dr. Renato Reyes of Central Luzon State University, who were present during the forum.

She clarified that it will not be a herbal supplement.

“It is a drug. That means it has a scientific basis to back up the efficacy of the anti-dengue drug,” Alvero explained.

De la Peña quipped: “That will be her [Alvero’s] Christmas gift [to us] next year.”

Montoya said he is “very excited” with the developments in making the anti-dengue drug.

“It is the very first in its class. No country, even the US, has an anti-dengue drug produced. We are looking forward to this,” he said.

The dengue drug project by Alvero started in 2012, for a processing period of eight years.

The dengue research was part of the DOST’s Tuklas Lunas program to produce reliable and affordable medicines sourced from the country’s rich biodiversity.

De la Peña said Tuklas Lunas has 28 centers all over the country and 28 research-implementing institutions. A total of P1.5 billion was invested in the program since it started in 2011.

Besides the anti-dengue drug being developed by Pharmalytics and De La Salle, a herbal supplement against dengue was developed by Herbanext Laboratories.

Herbanext’s herbal supplement from tawa-tawa, under the Daily Apple brand name, was released in August at the height of the dengue epidemic in the country.

Guevara said, “As we continue our path [on] the future of medicine development, DOST wishes to honor our Filipino knowledge and traditions in healing combined with the modern discoveries of research and development. This knowledge is a gift from our ancestors. As such, it will be a guide to learn from past mistakes, open new doors to discovery and provide us with courage to face the future. In this we hope for a tomorrow that will enable our countrymen to have cheap, safe, effective and easily accessible medicines.”

For his part, Montoya said, “We are very optimistic that this will happen. We have the best scientists, we have a rich biodiversity, which is the source of these natural medicines, and we have the support of the government, the Council and the department [DOST]. We have the best pool of scientists, of experts.”

He added: “We are very hopeful and optimistic that in the next few years, we are coming up with the very promising, very effective, affordable and safe drugs that will address the leading causes of morbidity and mortality [in the country].”


Sources: by: CJ M. Gonzales

The Department of Science and Technology (DOST) thru the Cagayan Valley Health Research and Development Consortium (CVHRDC) conducted its final training on basic Research Methods for this year at N-Hall, University of Saint Louis Tuguegarao last July 3-5, 2019.

During the opening ceremonies, Rev. Father Renillo H. Sta. Ana, University president immediately challenged the participants to improve the quality of health researches in the region by incorporating what they’ve learned from the three-day training.

“We do research for knowledge and truth. We do knowledge for mission and excellence.”, Fr. Renillo stressed as he concluded his message.

The 60 participants from different high schools, state universities, higher education institutions, and regional line agencies were tasked to draft a proposal concerning the pressing health issues of today.

The draft research proposals such as Multi-Drug Resistant Tuberculosis, Mental Health, Heavy Metal and Microbial Detection, Neglected Tropical Diseases, and Immunization were presented and panned during the training.

Meanwhile, presented proposals shall be improved and edited by the proponents to be submitted on August to the Technical Review Board for evaluation and endorsement of funding.

16th National Medical Writing Workshop and
9th Writeshop for Young Researchers

Cagayan de Oro, Philippines
 12-13 August 2019
Organized by the Philippine Council for Health Research and Development (PCHRD) and the 
Philippine Association of Medical Journal Editors (PAMJE),
Endorsed by the Asia Pacific Association of Medical Journal Editors (APAME)
Application deadline: May 15, 2019
REGISTRATION IS FREE (limited slots only)

The Department of Science and Technology - Philippine Council for Health Research and Development (DOST-PCHRD) in cooperation with Philippine Association of Medical Journal Editors (PAMJE) Inc. and Asia Pacific Association of Medical Journal Editors (APAME) is organizing the 16th National Medical Writing Workshop and 9th Writeshop for Young Researchers on 12-13 August 2019 in Cagayan De Oro. The workshop aims to help young investigators in health and health social sciences acquire practical knowledge and skills in preparing a scientific article for publication in a scholarly peer-reviewed journal. Successful applicants will be granted free workshop registration, accommodation and meals during the workshop, and will be assigned to a mentor-facilitator who will guide them in preparing their articles for a brief presentation.

Requirements for participants

The workshop is designed for a maximum of forty (40) researchers in health sciences and health social sciences, aged 40 years old and below, who have a research project completed not more than 2 years ago and have drafted a publication-ready manuscript of maximum 2,500 - 3,000 words, formatted for submission to a scholarly biomedical journal. Note that thesis, dissertations, and technical reports in original format and length do not qualify. 
The selected draft manuscripts will be reviewed and revised during the workshop, based on the lectures and exercises, under the guidance of the faculty and mentor – facilitators. All participants are expected to present a 7-minute power point summary of their revised manuscripts on the second day of the workshop, and agree to submit the article to an appropriate scholarly peer-reviewed journal within three (3) months after the workshop.


Applicants should send the following requirements via email to This email address is being protected from spambots. You need JavaScript enabled to view it. on or before May 15, 2019.
  1. Fill out the application form (Link:
  2. Conforme slip (Link:
  3. Abstract (in .docx and .pdf format)
  4. Draft of Journal Manuscript (in .docx and .pdf format) 
  5. Instructions to Authors for the target journal (This is a free document downloadable from the website of your prospective journal.)
Please use this subject format in your email: Application_16th Writeshop_(Surname)
Please save your documents in this format:
  • Conforme Slip_(Surname)
  • Abstract_(Surname)
  • Manuscript_(Surname)
  • ITA_(Surname)
The results of the selection of participants for the Workshop will be communicated on June 5, 2019.

Should you have any concern, do not hesitate to contact Ms. Quiella Landicho (e-mail address: This email address is being protected from spambots. You need JavaScript enabled to view it.; tel. no.: (02) 837-7534 loc. 203/204). 
Source: Dimailig, CJ. (April 24, 2019) Call for Participation: 16th National Medical Writing Workshop and 9th Writeshop for Young Researchers. retrive from:

Featured Links






Events Calendar

May 2020
26 27 28 29 30 1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30
31 1 2 3 4 5 6